Display options
Cite
Fessel J. If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic. Alzheimers Dement (N Y). 2020;6(1):e12019doi: 10.1002/trc2.12019.
Fessel, J. (2020). If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic. Alzheimer's & dementia (New York, N. Y.), 6(1), e12019. https://doi.org/10.1002/trc2.12019
Fessel, Jeffrey. "If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic." Alzheimer's & dementia (New York, N. Y.) vol. 6,1 (2020): e12019. doi: https://doi.org/10.1002/trc2.12019
Fessel J. If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic. Alzheimers Dement (N Y). 2020 May 06;6(1):e12019. doi: 10.1002/trc2.12019. eCollection 2020. PMID: 32382652; PMCID: PMC7202202.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (N Y). 2020 May 06;6(1):e12019. doi: 10.1002/trc2.12019. eCollection 2020.

If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic.

Alzheimer's & dementia (New York, N. Y.)

Jeffrey Fessel

Affiliations

  1. Department of Medicine University of California San Francisco California USA.

PMID: 32382652 PMCID: PMC7202202 DOI: 10.1002/trc2.12019

Abstract

If it is correct that ineffective levels of transforming growth factors beta and their receptor account for old age being a risk factor for Alzheimer's disease (AD), then increasing TGFBR2 might be therapeutic. Pacltaxel is a direct way to increase TGFBR2 levels. Indirect ways that will increase TGFBR2, include decreasing the levels of c-myc because that will lower the miRNA cluster 17-92, particularly its miR-17 and miR-20a components; and raising EGFR because that also will increase TGFBR2. Metformin and desferrioxamine are drugs that decrease c-myc; and statins increase levels of EGF. Clinical trials using those drugs, would demonstrate whether they decrease the progression from amnestic mild cognitive impairment to AD.

© 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.

References

  1. Biochim Biophys Acta. 2009 Jul;1793(7):1165-73 - PubMed
  2. Prog Neurobiol. 2009 May;88(1):64-75 - PubMed
  3. Neurology. 2006 Aug 8;67(3):467-73 - PubMed
  4. BMC Med Genomics. 2009 Jan 08;2:2 - PubMed
  5. Blood. 2007 May 15;109(10):4399-405 - PubMed
  6. Sci Rep. 2019 May 30;9(1):8079 - PubMed
  7. Haematologica. 2010 Aug;95(8):1325-33 - PubMed
  8. Nature. 2005 Jun 9;435(7043):839-43 - PubMed
  9. Sci Rep. 2015 Jun 10;5:11252 - PubMed
  10. Science. 1999 Jan 29;283(5402):676-9 - PubMed
  11. J Clin Invest. 2013 Mar;123(3):1348-58 - PubMed
  12. Carcinogenesis. 2013 Dec;34(12):2823-32 - PubMed
  13. Nat Commun. 2012 May 29;3:865 - PubMed
  14. Prog Brain Res. 2009;180:97-108 - PubMed
  15. Biochem Biophys Res Commun. 2004 Sep 10;322(1):105-9 - PubMed
  16. Int J Mol Sci. 2013 Jun 07;14(6):12273-96 - PubMed
  17. Circulation. 2007 Jan 2;115(1):27-33 - PubMed
  18. J Clin Oncol. 2006 Oct 20;24(30):4808-17 - PubMed
  19. Clin Diagn Lab Immunol. 1994 Jul;1(4):433-6 - PubMed
  20. Biomed Pharmacother. 2011 Feb;65(1):40-5 - PubMed
  21. Hippocampus. 2007;17(1):5-9 - PubMed
  22. Am J Pathol. 2006 Jul;169(1):154-64 - PubMed
  23. Biol Psychiatry. 2010 Nov 15;68(10):930-41 - PubMed
  24. Cancer Causes Control. 2009 Nov;20(9):1617-22 - PubMed
  25. J Neurosci. 2017 Jul 12;37(28):6797-6809 - PubMed
  26. Cancer Res. 2010 Oct 15;70(20):8233-46 - PubMed
  27. Cell Rep. 2013 Jun 27;3(6):2008-20 - PubMed
  28. Eur J Haematol. 1998 Jan;60(1):21-7 - PubMed
  29. FEBS Lett. 2012 Jul 4;586(14):1953-8 - PubMed
  30. Neuron. 2003 Dec 18;40(6):1133-45 - PubMed
  31. Lancet. 1991 Jun 1;337(8753):1304-8 - PubMed
  32. PLoS One. 2011 Jan 21;6(1):e16266 - PubMed
  33. Elife. 2019 May 09;8: - PubMed
  34. J Clin Invest. 2006 Nov;116(11):3060-9 - PubMed
  35. Neurology. 2007 Jul 10;69(2):133-9 - PubMed
  36. Cold Spring Harb Perspect Biol. 2016 May 02;8(5): - PubMed
  37. Biochem Biophys Res Commun. 2007 Jan 5;352(1):69-77 - PubMed
  38. Cancer Res. 2003 Aug 15;63(16):5095-104 - PubMed
  39. Alzheimers Dement (N Y). 2019 Dec 09;5:899-905 - PubMed
  40. Blood. 2002 Aug 1;100(3):912-6 - PubMed
  41. Front Cell Dev Biol. 2017 Feb 23;5:10 - PubMed
  42. J Physiol Paris. 2002 Jan-Mar;96(1-2):25-30 - PubMed
  43. J Cell Mol Med. 2014 Jul;18(7):1444-59 - PubMed
  44. J BUON. 2013 Apr-Jun;18(2):437-41 - PubMed
  45. Oncotarget. 2017 Jul 22;8(35):59235-59245 - PubMed

Publication Types